Bank of America's new price target has shares of Eli Lilly climbing 22% from here.
Get this delivered to your inbox, and more info about our products and services.
Leerink Partners sees shares of Eli Lilly adding another 19% from here.
The drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications
Combined sales for the company's blockbuster GLP-1 drugs Zepbound and Mounjaro exceeded $1 billion, with each showing…
Eli Lilly entered Thursday well off its highs. A blowout quarter shows the market got this one wrong.
Bank of America sees shares of Apple rising 19% from here.
Wall Street is optimistic heading into Eli Lilly's second-quarter earnings report.
